A fluorescent benzo[g]isoquinoline-based HIF prolyl hydroxylase inhibitor for cellular imaging

A fluorescent benzo[g]isoquinoline-based HIF prolyl hydroxylase inhibitor for cellular imaging

Prolyl hydroxylation domain (PHD) enzymes catalyze the hydroxylation of the transcription factor hypoxia‐inducible factor (HIF) and serve as cellular oxygen sensors. HIF and the PHD enzymes regulate numerous potentially tissue‐protective target genes which can adapt cells to metabolic and ischemic s...

Szczegółowa specyfikacja

Opis bibliograficzny
Główni autorzy:	Mayer, M, Fey, K, Heinze, E, Rainer Wick, C, Abboud, M, Yeh, T, Tumber, A, Orth, N, Schley, G, Buchholz, B, Clark, T, Schofield, C, Willam, C, Burzlaff, N
Format:	Journal article
Wydane:	Wiley 2018

Podobne zapisy

No benefit of HIF prolyl hydroxylase inhibition for hypertensive renal damage in renovascular hypertensive rats
od: Andrea Hartner, i wsp.
Wydane: (2023-06-01)

Tuning the transcriptional response to hypoxia by inhibiting HIF prolyl- and asparaginyl-hydroxylases
od: Chan, M, i wsp.
Wydane: (2016)

Molecular and Cellular Mechanisms of HIF Prolyl Hydroxylase inhibitors in Clinical Trials
od: Yeh, TL, i wsp.
Wydane: (2017)

The use of dioxygen by HIF prolyl hydroxylase (PHD1).
od: McNeill, L, i wsp.
Wydane: (2002)

2-oxoglutarate analogue inhibitors of HIF prolyl hydroxylase.
od: Mole, D, i wsp.
Wydane: (2003)

Lack of activity of recombinant HIF prolyl hydroxylases (PHDs) on reported non-HIF substrates
od: Cockman, M, i wsp.
Wydane: (2019)

Regulation of HIF: prolyl hydroxylases.
od: Stolze, I, i wsp.
Wydane: (2006)

Structural basis for oxygen degradation domain selectivity of the HIF prolyl hydroxylases
od: Chowdhury, R, i wsp.
Wydane: (2016)

Analogues of dealanylalahopcin are inhibitors of human HIF prolyl hydroxylases.
od: Schlemminger, I, i wsp.
Wydane: (2003)

Inhibition of a viral prolyl hydroxylase
od: Langley, G, i wsp.
Wydane: (2019)

Selective small molecule probes for the hypoxia inducible factor (HIF) prolyl hydroxylases.
od: Chowdhury, R, i wsp.
Wydane: (2013)

Lack of activity of recombinant HIF prolyl hydroxylases (PHDs) on reported non-HIF substrates
od: Matthew E Cockman, i wsp.
Wydane: (2019-09-01)

Structure–activity relationship and crystallographic studies on 4-hydroxypyrimidine HIF prolyl hydroxylase domain inhibitors
od: Holt-Martyn, JP, i wsp.
Wydane: (2019)

Exploring the substrate selectivity of oxygen sensing prolyl hydroxylases
od: Lippl, K, i wsp.
Wydane: (2015)

Structural basis for oxygen degradation domain selectivity of the HIF prolyl hydroxylases
od: Rasheduzzaman Chowdhury, i wsp.
Wydane: (2016-08-01)

Determination and comparison of specific activity of the HIF-prolyl hydroxylases.
od: Tuckerman, JR, i wsp.
Wydane: (2004)

HIF prolyl hydroxylases in the rat; organ distribution and changes in expression following hypoxia and coronary artery ligation.
od: Willam, C, i wsp.
Wydane: (2006)

Selective inhibitors of a human prolyl hydroxylase (OGFOD1) involved in ribosomal decoding
od: Thinnes, C, i wsp.
Wydane: (2018)

HIF prolyl hydroxylase inhibition prior to transient focal cerebral ischaemia is neuroprotective in mice.
od: Chen, R, i wsp.
Wydane: (2014)

HIF prolyl hydroxylase inhibition prior to transient focal cerebral ischaemia is neuroprotective in mice
od: Chen, R, i wsp.
Wydane: (2014)

Investigating the dependence of the hypoxia-inducible factor hydroxylases (factor inhibiting HIF and prolyl hydroxylase domain 2) on ascorbate and other reducing agents.
od: Flashman, E, i wsp.
Wydane: (2010)

Inhibition of HIF-prolyl hydroxylases improves healing of intestinal anastomoses
od: Moritz J. Strowitzki, i wsp.
Wydane: (2021-04-01)

Mutation Analysis of HIF-prolyl hydroxylases (PHD/EGLN) in Inherited Phaeochromocytoma and Renal Cell Carcinoma
od: Astuti, D, i wsp.
Wydane: (2010)

HIF prolyl and asparaginyl hydroxylases in the biological response to intracellular O(2) levels.
od: Masson, N, i wsp.
Wydane: (2003)

Studies on spiro[4.5]decanone prolyl hydroxylase domain inhibitors
od: Holt-Martyn, J, i wsp.
Wydane: (2019)

The HIF prolyl hydroxylase PHD3 is a potential substrate of the TRiC chaperonin.
od: Masson, N, i wsp.
Wydane: (2004)

Prolyl hydroxylases and therapeutics.
od: Smith, T, i wsp.
Wydane: (2010)

Tissue expression and functional insights into HIF prolyl hydroxylase domain enzymes
od: Wijeyekoon, JB
Wydane: (2013)

Neuroprotective Effect of HIF Prolyl Hydroxylase Inhibition in an In Vitro Hypoxia Model
od: Maria Savyuk, i wsp.
Wydane: (2020-07-01)

HIF Prolyl Hydroxylase Inhibitors for COVID-19 Treatment: Pros and Cons
od: Andrey A. Poloznikov, i wsp.
Wydane: (2021-01-01)

Hypoxia-inducible factor (HIF) prolyl hydroxylase inhibitors induce autophagy and have a protective effect in an in-vitro ischaemia model
od: Singh, A, i wsp.
Wydane: (2020)

Dual-action inhibitors of HIF prolyl hydroxylases that induce binding of a second iron ion.
od: Yeoh, K, i wsp.
Wydane: (2013)

Oxygen sensing by HIF hydroxylases.
od: Schofield, C, i wsp.
Wydane: (2004)

Signalling hypoxia by HIF hydroxylases.
od: Schofield, C, i wsp.
Wydane: (2005)

Studies on the substrate selectivity of the hypoxia-inducible factor prolyl hydroxylase 2 catalytic domain
od: Abboud, M, i wsp.
Wydane: (2018)

Discovery of neuroprotective agents that inhibit human prolyl hydroxylase PHD2
od: Richardson, NL, i wsp.
Wydane: (2021)

Therapeutic manipulation of the HIF hydroxylases.
od: Nagel, S, i wsp.
Wydane: (2010)

Mass spectrometric studies on an oxygen sensing prolyl hydroxylase
od: Mecinovic, J, i wsp.
Wydane: (2007)

Structural, biochemical and inhibition studies on hypoxia-inducible factor (HIF) prolyl hydroxylases
od: Lippl, K
Wydane: (2018)

Impact of HIF prolyl hydroxylase inhibitors in heart failure patients with renal anemia
od: Takahiro Kambara, i wsp.
Wydane: (2024-03-01)